HORIZONFP7H2020
Institut Gustave Roussy
- Country
- FRFrance
- Defence projects
- 0
- Projects, all programmes
- 70
- As coordinator
- 13
- EU contribution (CORDIS)
- EUR 42,610,701
- Active
- 2008 to 2026
Projects
70 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| SilkFUSIONGenetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research | H2020 | 2017 | Participant | EUR 688,328 |
| CLINGLIOA Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma. | H2020 | 2017 | Participant | EUR 117,000 |
| TKI resistanceResistance mechanisms to tyrosine kinase inhibitors in solid tumors | H2020 | 2016 | Coordinator | EUR 1,500,000 |
| ALKATRASALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer | H2020 | 2015 | Participant | EUR 0 |
| IMMUTRAINTraining Network for the Immunotherapy of Cancer | H2020 | 2015 | Participant | EUR 262,876 |
| CANCER-IDCancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood | FP7 | 2015 | Participant | EUR 319,581 |
| MERITMutanome Engineered RNA Immuno-Therapy | FP7 | 2013 | Participant | EUR 453,750 |
| WINTHERWINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients | FP7 | 2013 | Coordinator | EUR 991,102 |
| EECEURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma | FP7 | 2013 | Participant | EUR 72,431 |
| RAIDSRational molecular Assessments and Innovative Drug Selection | FP7 | 2012 | Participant | EUR 545,693 |
| RESPONSIFYGenome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer | FP7 | 2012 | Participant | EUR 427,000 |
| CAReIOCANon-Invasive Optical Biopsy for Cancer Assessment using ultra high resolution Full-Field Optical Coherence Tomography | FP7 | 2012 | Participant | EUR 428,860 |
| MELENDO2Genetic epidemiological investigation into the association between endometriosis and cutaneous melanoma | FP7 | 2012 | Coordinator | EUR 268,555 |
| CTCTRAPCirculating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients | FP7 | 2012 | Participant | EUR 386,250 |
| BIOtracheaBiomaterials for Tracheal Replacement in Age-related Cancer via a Humanly Engineered Airway | FP7 | 2012 | Participant | EUR 80,400 |
| PANCARESURFUPPanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies | FP7 | 2011 | Participant | EUR 909,112 |
| ENS@T-CANCEREuropean Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults | FP7 | 2011 | Participant | EUR 434,432 |
| EUROSARCEuropean Clinical trials in Rare Sarcomas within an integrated translational trial network | FP7 | 2011 | Participant | EUR 206,425 |
| COMBIOMSTRENGTHENING COOPERATION IN MOLECULAR BIOMEDICINE BETWEEN EU AND UKRAINE | FP7 | 2011 | Participant | EUR 54,998 |
| PROCARDIOCardiovascular Risk from Exposure to Low-dose and Low-dose-rate Ionizing Radiation | FP7 | 2011 | Participant | EUR 269,560 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.